Ownership and insider activity for Adlai Nortye Ltd. (ANL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas.
Price
| Price | $15.52 |
| Market Cap | $824M |
| Exchange | NASDAQ |
| Country | SG |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-24 | Ye Xiaofeng | S-Sale | 6,000 | $84K |
| 2026-08-26 | Ye Xiaofeng | S-Sale | 5,667 | $81K |
| 2026-03-18 | Birgerson Lars Erik | |||
| 2026-03-18 | Sawhney Roger | |||
| 2026-03-18 | Sawhney Roger | 4,162 | ||
| 2026-06-10 | Ji Ping | J-Other | 136,667 | |
| 2026-05-28 | Ye Xiaofeng | |||
| 2026-05-28 | Ye Xiaofeng | |||
| 2020-09-08 | Ye Xiaofeng | 66,667 | $220K | |
| 2020-11-01 | Ye Xiaofeng | 2,584 | $14K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.0M | $24.2M | $64.1M | $42.8M | $91.5M | $60.9M | $23.8M |
| Short-term Investments | 0 | $241000 | $53.8M | $21.3M | $7.0M | $7000 | 0 |
| Receivables | $91591 | $394048 | $1.9M | $346000 | $359000 | $1.2M | $1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $6.4M | $28.6M | $124.5M | $66.3M | $101.2M | $64.1M | $26.9M |
| Property, Plant & Equipment | $3.3M | $6.6M | $6.6M | $5.9M | $3.8M | $2.7M | $3.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $115422 | $11000 | $97000 | $89000 | $63000 | $40000 | $19000 |
| Total Assets | $10.8M | $36.7M | $131.7M | $72.6M | $130.2M | $71.3M | $34.4M |
| Accounts Payable | $5.3M | $1.5M | $3.0M | $13.1M | $14.3M | $10.1M | $12.6M |
| Short-term Debt | $10.9M | $9.1M | $10.5M | $4.3M | $30.4M | $26.3M | $25.2M |
| Total Current Liabilities | $20.3M | $88.0M | $17.5M | $312.7M | $49.7M | $45.4M | $41.6M |
| Long-term Debt | $634250 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $80.2M | $168.3M | $317.1M | $313.9M | $55.1M | $45.8M | $42.8M |
| Retained Earnings | -$86.6M | -$159.2M | -$209.4M | -$268.2M | -$377.4M | -$429.3M | -$464.8M |
| Total Equity | -$69.4M | -$131.6M | -$185.4M | -$241.3M | $75.0M | $25.5M | -$8.3M |
| Total Debt | $11.9M | $11.0M | $13.3M | $6.5M | $31.5M | $27.2M | $26.4M |
| Net Debt | $5.9M | -$13.5M | -$104.6M | -$57.5M | -$67.0M | -$33.7M | $2.6M |
| Working Capital | -$13.9M | -$59.4M | $107.0M | -$246.3M | $51.5M | $18.7M | -$14.7M |
Financial Health
| Debt / Equity | 0.12 |
| Current Ratio | 9.55 |
Profitability
| Return on Equity | -21.82% |
| Return on Invested Capital | -9.23% |
| Return on Assets | -9.07% |
| Gross Margin | 100.00% |
| Operating Margin | -113.28% |
| Net Margin | -114.48% |
Related companies: ADAP · ADTX · AIMD · APLM · BLRX · GOVX · ICU
Explore sector: Healthcare · Biotechnology
More sections of ANL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks